A Neonate with Hyperammonemia and a Normal Plasma Citrulline: Choosing the Next Test Under Time Pressure
A 4-day-old term male, birth weight 3.2 kg, breastfed, presents with lethargy and poor feeding that began ~30 hours after birth. Exam: tachypnea, hypotonia, no dysmorphism. Labs: plasma ammonia 480 micromol/L (ref <100), pH 7.48, pCO2 24 mmHg, bicarbonate 18 mmol/L, anion gap 14, glucose 4.1 mmol/L, lactate 1.6 mmol/L, AST/ALT normal, total bilirubin 6 mg/dL. Plasma amino acids: citrulline 8 micromol/L (low-normal), arginine 22 micromol/L, glutamine markedly elevated, alanine elevated. Urine organic acids: no orotic acid reported, no specific organic aciduria. Blood gas shows respiratory alkalosis. The laboratory's quantitative plasma amino acid turnaround is 48 hours; urine orotic acid by GC-MS is available next morning. Newborn screening (collected at 26 hours) is reported as 'pending, repeat requested.'
1. Which single next test would most efficiently discriminate between the leading diagnostic possibilities, and what result pattern would you expect for each?
Read the worked answer
Leading differential: a proximal urea cycle defect (carbamoyl phosphate synthetase I [CPS1] or ornithine transcarbamylase [OTC] deficiency) vs. a distal defect, vs. a transient/other cause. Low-normal citrulline plus respiratory alkalosis and no organic aciduria points to a proximal urea cycle disorder.
Best next test: urine orotic acid (quantitative). Reasoning:
- OTC deficiency: orotic acid is markedly increased (carbamoyl phosphate accumulates and is shunted to pyrimidine synthesis), with low citrulline and elevated glutamine/alanine.
- CPS1 deficiency: orotic acid is low or normal (carbamoyl phosphate is not made), with low citrulline.
- ASS1 (citrullinemia type I): citrulline would be markedly elevated, not low - effectively excluded here.
- ASL (argininosuccinic aciduria): argininosuccinate elevated, citrulline elevated - excluded.
- NAGS deficiency: biochemically resembles CPS1 (low orotic acid, low citrulline).
Because OTC is X-linked, sex and family history matter for counseling, but the immediate branch point is orotic acid. A normal/low orotic acid with low citrulline shifts you toward CPS1/NAGS; a high orotic acid shifts you toward OTC. Do not wait for the repeat newborn screen.
2. The urine orotic acid returns markedly elevated. Plasma citrulline is 8 micromol/L. How do you reconcile these, and what does this imply for immediate management and confirmation?
Read the worked answer
Markedly elevated orotic acid with low citrulline and hyperammonemia is the classic signature of OTC deficiency (X-linked). Carbamoyl phosphate accumulates because OTC cannot condense it with ornithine; excess carbamoyl phosphate is diverted into pyrimidine synthesis, producing orotic acid. Low citrulline follows because citrulline is downstream of OTC.
Immediate management (do not wait for confirmation):
- Stop protein intake temporarily; provide calories as IV glucose (and lipids) to reverse catabolism; maintain hydration.
- Give nitrogen-scavenging therapy - sodium phenylbutyrate (or sodium benzoate) plus arginine (or citrulline) to provide substrate and drive the cycle - per institutional protocol.
- If ammonia is very high or rising despite scavengers, arrange hemodialysis (more effective than CRRT for ammonia clearance in neonates).
- Avoid valproate; review all meds.
- Monitor ammonia frequently, watch for cerebral edema.
Confirmation: plasma glutamine and ammonia trend, plus molecular testing of OTC (targeted sequencing/deletion analysis). Enzyme assay on liver is generally not required and is invasive. Because OTC is X-linked, test the mother too - she may be an asymptomatic carrier with skewed X-inactivation, which affects recurrence counseling. Newborn screening for OTC is insensitive; a normal NBS does not exclude it.
3. The family asks about recurrence risk and whether the mother could be a carrier. What is your counseling approach before molecular results return?
Read the worked answer
Before results: be explicit that the recurrence risk depends on the diagnosis and the mother's carrier status, and avoid giving a single number prematurely.
- If OTC deficiency is confirmed and the mother is a carrier: each pregnancy has a 50% chance of inheriting the variant. For a male, an inherited variant typically causes severe neonatal disease; for a female, expression is variable (skewed X-inactivation), ranging from asymptomatic to severe. A carrier mother may herself be at risk and should be evaluated.
- If the mother is NOT a carrier: the variant is likely de novo in the child; recurrence risk is low (empiric ~1% or less, accounting for possible germline mosaicism).
- If the diagnosis were CPS1 or NAGS (autosomal recessive): recurrence risk would be 25% per pregnancy regardless of sex, and both parents would be obligate carriers.
Practical steps: offer carrier testing of the mother (and cascade testing of at-risk relatives if she is a carrier), prenatal diagnosis by chorionic villus sampling or amniocentesis once the familial variant is known, and discussion of preimplantation genetic testing. Emphasize that a normal newborn screen in future pregnancies does not reliably exclude OTC, so biochemical monitoring of an at-risk neonate is warranted regardless of NBS result.